Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
暂无分享,去创建一个
[1] Nan Li,et al. Corrigendum to "TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance" [Mol. Immunol. 44 (2007) 2850-2859]. , 2020, Molecular immunology.
[2] M. Lunning,et al. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL , 2019, Current Hematologic Malignancy Reports.
[3] K. Giannopoulos,et al. Deregulation of the immune system in patients with chronic lymphocytic leukemia , 2019, Postępy Higieny i Medycyny Doświadczalnej.
[4] J. D. Díaz Arias,et al. Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns , 2019, Front. Oncol..
[5] Huihao Zhang,et al. TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells , 2018, Molecular medicine reports.
[6] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.
[7] Jae Young Kim,et al. Identification and Characterization of a Splicing Variant in the 5′ UTR of the Human TLR5 Gene , 2017, BioMed research international.
[8] Jian-yong Li,et al. MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene , 2017, Blood Cancer Journal.
[9] K. Kuliczkowski,et al. The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia , 2016, Archivum Immunologiae et Therapiae Experimentalis.
[10] A. Karczmarczyk,et al. Specific cytotoxic T‐cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells , 2016, British journal of haematology.
[11] P. Moss,et al. Perturbation of the normal immune system in patients with CLL. , 2015, Blood.
[12] A. Karczmarczyk,et al. Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia , 2015, Acta Haematologica.
[13] Huihao Zhang,et al. Significance of TLR4/MyD88 expression in breast cancer. , 2015, International journal of clinical and experimental pathology.
[14] K. Horikawa,et al. Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation , 2014, Front. Immunol..
[15] Dong Chang Lee,et al. Toll like Receptor 3 & 4 Responses of Human Turbinate Derived Mesenchymal Stem Cells: Stimulation by Double Stranded RNA and Lipopolysaccharide , 2014, PloS one.
[16] K. Stamatopoulos,et al. Heterogeneous Functional Effects of Concomitant B Cell Receptor and TLR Stimulation in Chronic Lymphocytic Leukemia with Mutated versus Unmutated Ig Genes , 2014, The Journal of Immunology.
[17] D. Klinman,et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors , 2014, Journal of Immunotherapy for Cancer.
[18] D. Consonni,et al. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression , 2014, Leukemia & lymphoma.
[19] N. Rezaei,et al. Toll-like receptors in lymphoid malignancies: double-edged sword. , 2014, Critical reviews in oncology/hematology.
[20] F. caligaris-Cappio,et al. How the microenvironment wires the natural history of chronic lymphocytic leukemia. , 2014, Seminars in cancer biology.
[21] X. Sheng,et al. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro , 2013, Oncology letters.
[22] M. Zając,et al. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. , 2013, Human immunology.
[23] P. Pilarski,et al. A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets , 2013, Clinical Cancer Research.
[24] G. Trinchieri,et al. MyD88 and its divergent toll in carcinogenesis. , 2013, Trends in immunology.
[25] A. Dmoszyńska,et al. Aberrant TIRAP and MyD88 expression in B-cell chronic lymphocytic leukemia. , 2013, Blood cells, molecules & diseases.
[26] Jing Yang,et al. Toll‐like receptor‐4 signaling in mantle cell lymphoma , 2013, Cancer.
[27] A. Dmoszyńska,et al. TLR2 may influence the behavior of the malignant clone in B-CLL. , 2012, Blood cells, molecules & diseases.
[28] L. Llorente,et al. Immunological aspects in chronic lymphocytic leukemia (CLL) development , 2012, Annals of Hematology.
[29] M. I. Crespo,et al. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. , 2012, Cancer research.
[30] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[31] Stavroula Ntoufa,et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients , 2011, Haematologica.
[32] N. Chiorazzi,et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. , 2010, Blood.
[33] R. Spíšek,et al. Toll‐like receptors on B‐CLL cells: expression and functional consequences of their stimulation , 2010, International journal of cancer.
[34] M. Vega,et al. The significance of toll-like receptors in human diseases. , 2009, Allergologia et immunopathologia.
[35] T. Whiteside,et al. TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.
[36] Paolo Ghia,et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells , 2009, British journal of haematology.
[37] R. Rosenquist,et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.
[38] P. Feugier,et al. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells , 2007, Haematologica.
[39] Jun Kawai,et al. Alternate transcription of the Toll-like receptor signaling cascade , 2006, Genome Biology.
[40] A. Lanzavecchia,et al. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. , 2003, Blood.
[41] G Leone,et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease , 2007, Leukemia.